XENE
Xenon to Present at Upcoming Investor Conferences
Article Summary
HOLD- Xenon Pharmaceuticals Inc. (Nasdaq: XENE) announced that Xenon Pharmaceuticals will present at four upcoming investor conferences in the second quarter of 2026, with the neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need.
- Xenon's lead molecule,azetukalner, is a novel, potent, selective KV7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD), and bipolar depression (BPD), with the company advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators in Phase 1 development for potential treatment of pain.
- Details about all company presentations, including webcast information, can be found on the Investors section of Xenon's website.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 0.0% | 25% | 20.0 ptsMinimal (0.0%) - Very weak |
| EPS Growth Next 5Y ? | 12.5% | 25% | 35.0 ptsBelow Screener (12.5%) - Modest outlook |
| Target Price Upside ? | 33.6% | 20% | 85.0 ptsLarge Upside (33.6%) - Target: $79.24 vs Current: $59.29 |
| Gross Margin % ? | 66.1% | 15% | 80.0 ptsVery Healthy (66.1%) - High-quality margins |
| Drawdown from 52-Wk High ? | -7.3% | 15% | 20.0 ptsBarely a Dip (-7.3%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About XENE
- Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders.
- Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.
- In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain.
- The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy.
- Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.